90Yttrium-ibritumomab tiuxetan: A novel treatment for non-Hodgkin's lymphoma

Kristie A. Blum, Nancy L. Bartlett

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Indolent non-Hodgkin's lymphomas (NHLs) comprise 35-40% of all adult NHLs. No standard curative therapy exists for these malignancies. Newer therapies, including monoclonal antibodies and radioimmunotherapy, have had notable activity in chemotherapy-resistant patients. 90Yttrium-ibritumomab tiuxetan is a radioimmunoconjugate approved by the Food and Drug Administration in February 2002 for the treatment of relapsed and refractory, low-grade, follicular or transformed NHL. Reported response rates are 67-80%, with a median remission duration of ∼ 12 months. Toxicities are primarily neutropenia and thrombocytopenia, with few infectious complications. 90Yttrium- ibritumomab tiuxetan is an effective therapeutic alternative for the treatment of NHL.

Original languageEnglish
Pages (from-to)1323-1331
Number of pages9
JournalExpert opinion on biological therapy
Issue number8
StatePublished - Aug 2004


  • Monoclonal antibody
  • Non-Hodgkin's lymphoma
  • Radioimmunoconjugate
  • Radioimmunotherapy
  • Yttrium-ibritumomab tiuxetan


Dive into the research topics of '90Yttrium-ibritumomab tiuxetan: A novel treatment for non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

Cite this